عرض بسيط للتسجيلة

المؤلفMestiri, Sarra
المؤلفMerhi, Maysaloun
المؤلفInchakalody, Varghese P.
المؤلفTaib, Nassiba
المؤلفSmatti, Maria K.
المؤلفAhmad, Fareed
المؤلفRaza, Afsheen
المؤلفAli, Fatma H.
المؤلفHydrose, Shereena
المؤلفFernandes, Queenie
المؤلفAnsari, Abdul W.
المؤلفSahir, Fairooz
المؤلفAl-Zaidan, Lobna
المؤلفJalis, Munir
المؤلفGhoul, Mokhtar
المؤلفAllahverdi, Niloofar
المؤلفAl Homsi, Mohammed U.
المؤلفUddin, Shahab
المؤلفJeremijenko, Andrew Martin
المؤلفNimir, Mai
المؤلفAbu-Raddad, Laith J.
المؤلفAbid, Fatma Ben
المؤلفZaqout, Ahmed
المؤلفAlfheid, Sameer R.
المؤلفSaqr, Hassan Mohamed Hassan
المؤلفOmrani, Ali S.
المؤلفHssain, Ali Ait
المؤلفAl Maslamani, Muna
المؤلفYassine, Hadi M.
المؤلفDermime, Said
تاريخ الإتاحة2023-03-28T07:18:57Z
تاريخ النشر2023-02-02
اسم المنشورFrontiers in Immunology
المعرّفhttp://dx.doi.org/10.3389/fimmu.2023.1061255
الاقتباسMestiri S, Merhi M, Inchakalody VP, Taib N, Smatti MK, Ahmad F, Raza A, Ali FH, Hydrose S, Fernandes Q, Ansari AW, Sahir F, Al-Zaidan L, Jalis M, Ghoul M, Allahverdi N, Al Homsi MU, Uddin S, Jeremijenko AM, Nimir M, Abu-Raddad LJ, Abid FB, Zaqout A, Alfheid SR, Saqr HMH, Omrani AS, Hssain AA, Al Maslamani M, Yassine HM and Dermime S (2023) Persistence of spike-specific immune responses in BNT162b2-vaccinated donors and generation of rapid ex-vivo T cells expansion protocol for adoptive immunotherapy: A pilot study. Front. Immunol. 14:1061255. doi: 10.3389/fimmu.2023.1061255
معرّف المصادر الموحدhttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85148344598&origin=inward
معرّف المصادر الموحدhttp://hdl.handle.net/10576/41362
الملخصIntroduction: The BNT162b2 mRNA-based vaccine has shown high efficacy in preventing COVID-19 infection but there are limited data on the types and persistence of the humoral and T cell responses to such a vaccine. Methods: Here, we dissect the vaccine-induced humoral and cellular responses in a cohort of six healthy recipients of two doses of this vaccine. Results and discussion: Overall, there was heterogeneity in the spike-specific humoral and cellular responses among vaccinated individuals. Interestingly, we demonstrated that anti-spike antibody levels detected by a novel simple automated assay (Jess) were strongly correlated (r=0.863, P<0.0001) with neutralizing activity; thus, providing a potential surrogate for neutralizing cell-based assays. The spike-specific T cell response was measured with a newly modified T-spot assay in which the high-homology peptide-sequences cross-reactive with other coronaviruses were removed. This response was induced in 4/6 participants after the first dose, and all six participants after the second dose, and remained detectable in 4/6 participants five months post-vaccination. We have also shown for the first time, that BNT162b2 vaccine enhanced T cell responses also against known human common viruses. In addition, we demonstrated the efficacy of a rapid ex-vivo T cell expansion protocol for spike-specific T cell expansion to be potentially used for adoptive-cell therapy in severe COVID-19, immunocompromised individuals, and other high-risk groups. There was a 9 to 13.7-fold increase in the number of expanded T cells with a significant increase of anti-spike specific response showing higher frequencies of both activation and cytotoxic markers. Interestingly, effector memory T cells were dominant in all four participants’ CD8+ expanded memory T cells; CD4+ T cells were dominated by effector memory in 2/4 participants and by central memory in the remaining two participants. Moreover, we found that high frequencies of CD4+ terminally differentiated memory T cells were associated with a greater reduction of spike-specific activated CD4+ T cells. Finally, we showed that participants who had a CD4+ central memory T cell dominance expressed a high CD69 activation marker in the CD4+ activated T cells.
راعي المشروعThis research was funded by Academic Health System, Medical Research Center, Hamad Medical Corporation, Doha, Qatar, grant number MRC-01-21-113, and the Article Processing Charges was funded by Academic Health System, Medical Research Center, Hamad Medical Corporation, Doha, Qatar. The funder was not involved in the study design, collection, analysis, interpretation of data, the writing of this article, or the decision to submit it for publication.
اللغةen
الناشرFrontiers Media
الموضوعCOVID-19 vaccine
SARS-CoV-2
spike-specific immune responses
spike-specific T cells expansion
surrogate neutralization
العنوانPersistence of spike-specific immune responses in BNT162b2-vaccinated donors and generation of rapid ex-vivo T cells expansion protocol for adoptive immunotherapy: A pilot study
النوعArticle
رقم المجلد14
ESSN1664-3224
dc.accessType Open Access


الملفات في هذه التسجيلة

Thumbnail

هذه التسجيلة تظهر في المجموعات التالية

عرض بسيط للتسجيلة